Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Receivables (2016 - 2025)

Phibro Animal Health (PAHC) has 13 years of Receivables data on record, last reported at $215.9 million in Q4 2025.

  • For Q4 2025, Receivables rose 12.56% year-over-year to $215.9 million; the TTM value through Dec 2025 reached $215.9 million, up 12.56%, while the annual FY2025 figure was $228.0 million, 34.54% up from the prior year.
  • Receivables reached $215.9 million in Q4 2025 per PAHC's latest filing, down from $217.9 million in the prior quarter.
  • Across five years, Receivables topped out at $228.0 million in Q2 2025 and bottomed at $135.6 million in Q1 2021.
  • Average Receivables over 5 years is $167.3 million, with a median of $158.7 million recorded in 2022.
  • Peak YoY movement for Receivables: fell 10.55% in 2021, then skyrocketed 35.53% in 2025.
  • A 5-year view of Receivables shows it stood at $142.5 million in 2021, then grew by 6.55% to $151.8 million in 2022, then fell by 0.79% to $150.6 million in 2023, then increased by 27.33% to $191.8 million in 2024, then grew by 12.56% to $215.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $215.9 million in Q4 2025, $217.9 million in Q3 2025, and $228.0 million in Q2 2025.